RxDoctor Payments Data

Jeffrey Cavendish, MD

Interventional Cardiology · San Diego, CANPI 1093787889

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.7% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Edwards Lifesciences at 41.9% of the total. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.

$3,246in general payments, 2019–2025

Across 51 payments — averaging $63.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Abbott$633
  • Medtronic$579
  • Abiomed$339
  • Cathworks, Inc.$104
  • Boston Scientific$82
  • plus $148 from 5 others
$351,978in research payments, 2019–2025

Across 86 payments — averaging $4092.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$284K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$33K
  • Boehringer Ingelheim International GmbH$32K
  • Edwards Lifesciences$4K

What the payments were for

  • Travel & lodging$2708%
  • Food & beverage$2,97692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,246 in reported general payments places this provider in the 30th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$2,533
Medicare patients
27
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$83,834
Repatha SureclickEvolocumab26$42,836
PradaxaDabigatran Etexilate Mesylate88$25,181
Repatha PushtronexEvolocumab27$24,471
JardianceEmpagliflozin20$8,305
Prasugrel Hcl60$3,989
Flecainide Acetate81$3,112
ClopidogrelClopidogrel Bisulfate161$3,045
Atorvastatin Calcium225$2,931
Metoprolol Tartrate166$1,805
Rosuvastatin Calcium138$1,610
Amiodarone Hcl53$1,351
Furosemide83$1,131
Carvedilol89$1,042
Potassium Chloride45$1,019

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →